Specify Company / Ticker to Get the Summary
Dividend History AVIR
Dividend Analytics AVIR
Max Ratio
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Atea Pharmaceuticals Inc
AVIRAtea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts. Address: 225 Franklin Street, Boston, MA, United States, 02110
Analytics
WallStreet Target Price
7.50 USDP/E Ratio
–Dividend Yield
–Financials AVIR
Results | 2019 | Dynamics |